vegf a 121  (R&D Systems)

Journal: Cell Reports

Article Title: The HIF transcription network exerts innate antiviral activity in neurons and limits brain inflammation

doi: 10.1016/j.celrep.2024.113792

Figure Lengend Snippet:

Article Snippet: VEGF-121 , Peprotech , #100-20A.

Techniques: Virus, Variant Assay, Recombinant, Isolation, Extraction, SYBR Green Assay, Enzyme-linked Immunosorbent Assay, Sample Prep, Expressing, Software, Imaging, Modification, Knock-Out

Journal: Journal of Food Biochemistry

Article Title: A Novel Pentapeptide From Tilapia Skin Gelatin Gastrointestinal Digests Which Inhibits Scar Formation Through Anti‐Inflammatory and Antiangiogenesis

doi: 10.1155/jfbc/8863473

Figure Lengend Snippet: Figure 3: Efect of LYG on VEGF-induced (10 ng/mL) in HUVECs. (a) Inhibition of HUVECs migration by LYG; (b) inhibition of HUVECs invasion by LYG; (c) inhibition of HUVECs tube formation by LYG; and (d) inhibition of ROS and NO in HUVECs by LYG.

Article Snippet: Te Human vascular endothelial growth factor (VEGF) and antibodies were provided by Cell Signaling Technology (MA, USA), Signalway Antibody (USA), and Santa Cruz Biotechnology (CA, USA).

Techniques: Inhibition, Migration

Journal: Journal of Food Biochemistry

Article Title: A Novel Pentapeptide From Tilapia Skin Gelatin Gastrointestinal Digests Which Inhibits Scar Formation Through Anti‐Inflammatory and Antiangiogenesis

doi: 10.1155/jfbc/8863473

Figure Lengend Snippet: Figure 5: Efect of LYG on VEGF-induced (10 ng/mL) angiogenesis-related protein expression in HUVECs. (a) Expression of key an- giogenic proteins in HUVECs; (b) secretion of MMP-2/-9 and angiogenic factors in HUVECs; (c) expression of MMPs in HUVECs; (d) expression of MMP-2/-9 in HUVECs; (e) expression of the MAPK signaling pathway in HUVECs; (f) expression of the PI3K/AKT signaling pathway in HUVECs; (g) expression of the NF-κB signaling pathway in HUVECs; (h) expression level of p65 nuclear protein.

Article Snippet: Te Human vascular endothelial growth factor (VEGF) and antibodies were provided by Cell Signaling Technology (MA, USA), Signalway Antibody (USA), and Santa Cruz Biotechnology (CA, USA).

Techniques: Expressing

Journal: Journal of Orthopaedic Translation

Article Title: Elevated secretion of pro-collagen I-alpha and vascular endothelial growth factor as biomarkers of acetabular labrum degeneration and calcification in hip osteoarthritis: An explant study

doi: 10.1016/j.jot.2023.08.007

Figure Lengend Snippet: Hierarchical clustering of baseline biomarker profiles in hip OA labra indicates distinct subgroups based on presence of calcification. Scatter plot of Pro-Col-Iα levels versus VEGF (A) and COMP (B) . Regression line with 95% confidence intervals is depicted. (C) Biomarker levels were normalized to the average of the entire sample and depicted clusters were generated using average linkage clustering based on correlation distance. Compared to fracture controls, OA labra exhibited elevated expression of Pro-Col-Iα, COMP, and VEGF.

Article Snippet: Secreted protein levels were assessed by commercial ELISA kits for Pro-Col-Iα (Abcam, ab216064, sample dilution 1:100), aggrecan (RayBiotech, ELH-ACAN-1, sample dilution 1:3), COMP (Sino Biological, SEK10173, sample dilution 1:500), vascular endothelial growth factor (VEGF)-121 (Sino Biological, SEK10008, sample dilution 1:2) and IL-6 (Invitrogen, 88-7066-86, sample dilution 1:400).

Techniques: Biomarker Assay, Generated, Expressing

Journal: Journal of Orthopaedic Translation

Article Title: Elevated secretion of pro-collagen I-alpha and vascular endothelial growth factor as biomarkers of acetabular labrum degeneration and calcification in hip osteoarthritis: An explant study

doi: 10.1016/j.jot.2023.08.007

Figure Lengend Snippet: Regulation of biomarker secretion through TGF-beta signaling. (A – E) Secretion of indicated biomarkers in fracture controls (Frx), non-calcified (OA-NC) and calcified OA (OA-C) labrum tissues treated with vehicle (blue) or TGF-beta receptor I inhibitor (grey). (F) Scatter plot of the relative change in Pro-Col-Iα and VEGF secretion between vehicle and TGF-beta receptor I inhibitor treatments. ∗ P ​< ​0.05 by Tukey's post-hoc test. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Article Snippet: Secreted protein levels were assessed by commercial ELISA kits for Pro-Col-Iα (Abcam, ab216064, sample dilution 1:100), aggrecan (RayBiotech, ELH-ACAN-1, sample dilution 1:3), COMP (Sino Biological, SEK10173, sample dilution 1:500), vascular endothelial growth factor (VEGF)-121 (Sino Biological, SEK10008, sample dilution 1:2) and IL-6 (Invitrogen, 88-7066-86, sample dilution 1:400).

Techniques: Biomarker Assay